New pneumonia vaccine candidate enters early human safety testing

NCT ID NCT07168915

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 4 times

Summary

This early-stage study is testing a new vaccine called V118E to see if it is safe and well-tolerated in healthy adults. The vaccine aims to protect against infections caused by Streptococcus pneumoniae bacteria, which can cause pneumonia and other serious illnesses. Around 126 healthy volunteers will receive the vaccine and be monitored for side effects like injection-site pain, fever, and tiredness. The study does not yet measure how well the vaccine works, only its safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)
RECRUITING

Springfield, Missouri, 65802, United States

Contact Phone: •••-•••-••••
QPS-MRA, LLC-Early Phase ( Site 0002)
ACTIVE_NOT_RECRUITING

South Miami, Florida, 33143, United States
University of Texas Medical Branch ( Site 0001)
ACTIVE_NOT_RECRUITING

Galveston, Texas, 77555-1115, United States
Velocity Clinical Research, Hallandale Beach ( Site 0003)
RECRUITING

Hallandale, Florida, 33009, United States

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.